Durapore vs. Hy-Tape to Secure The Endotracheal Tube

Sponsor
Tufts Medical Center (Other)
Overall Status
Completed
CT.gov ID
NCT03633877
Collaborator
(none)
112
1
2
12.8
8.8

Study Details

Study Description

Brief Summary

While adhesive tape is commonly used to secure endotracheal tubes (ETT) during general anesthesia, its use is also associated with facial skin injuries. Although a variety of adhesive tapes are used in clinical practice, few studies have investigated the likelihood of adhesives in producing injury. The purpose of this randomized, controlled, non-inferiority study was to compare the proportion of facial skin injury with Durapore™ vs. Hy-Tape®.

Condition or Disease Intervention/Treatment Phase
  • Device: DuraporeTM and Hy-Tape®
N/A

Detailed Description

Adhesive tapes are often used on the patient's face during general anesthesia. They are used to fix the tracheal tube, nasopharyngeal temperature probe, nasogastric tube, and nerve stimulator electrodes. An adhesive tape used in anesthesia needs to provide fast, secure adhesion to prevent dislodgement of critical devices. The tape should be secure over time, with changes over temperature, humidity, or exposure to fluids as occurring in the operating room. However, the tape should be gentle enough that removal should not cause skin trauma to the face. While the skin irritation is generally limited to mild erythema that resolves on its own within a day or two of receiving anesthesia, the irritation may affect patient satisfaction. Furthermore, serious injury, including full-thickness epidermal loss with purpura has occurred at Tufts Medical Center with the use of 3MTM Durapore tape, requiring several doctor visits in follow up.

Medical adhesive related skin injuries are estimated to impact at least 1.5 million patients annually in the US with significant costs per incident. (1) At Tufts Medical Center, a variety of adhesive tapes are used to secure the endotracheal tube during anesthesia, including 3MTM Durapore (acrylate- based tape) and the Hy-Tape® Pink tape (zink-based tape) with no preference for one or the other.

Hy-Tape's zinc oxide-based adhesive is claimed to be soothing to delicate skin, and removes with minimum trauma, thereby reducing the chance of skin tears and tape burns. It also has the unique quality of providing maximum adhesion when it reaches body temperature, without getting more aggressive or breaking down over time as acrylic-based adhesive tapes do. However, there is no scientific evidence to support this claim.

The purpose of this study is to compare the proportion of skin erythema after general anesthesia with the use of DuraporeTM vs. Hy-Tape®.

Study Design

Study Type:
Interventional
Actual Enrollment :
112 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Every patient will have each tape on each side of the mouth, with Hy-Tape® on one side and DuraporeTM on the other side according to the randomization schema.Every patient will have each tape on each side of the mouth, with Hy-Tape® on one side and DuraporeTM on the other side according to the randomization schema.
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
A Prospective Randomized Trial of Durapore vs. Hy-Tape to Secure the Endotracheal Tube During Anesthesia.
Actual Study Start Date :
Sep 17, 2018
Actual Primary Completion Date :
Oct 11, 2019
Actual Study Completion Date :
Oct 11, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: DuraporeTM on R, Hy-Tape ® on L

DuraporeTM and Hy-Tape® will be placed on patients' skin around the mouth during general anesthesia

Device: DuraporeTM and Hy-Tape®
Medical tapes

Experimental: DuraporeTM on L, Hy-Tape ® on R

DuraporeTM and Hy-Tape® will be placed on patients' skin around the mouth during general anesthesia

Device: DuraporeTM and Hy-Tape®
Medical tapes

Outcome Measures

Primary Outcome Measures

  1. Skin erythema [Standardized photos will be taken within 5 minutes of removing tape after surgery]

    Skin photographs will be independently evaluated by three blinded dermatologists to determine presence and severity of perioral erythema. Photographs will be cropped such that only the perioral region is visible for assessment. Erythema will be evaluated on a scale of 0-3 (0 indicating none, 1 indicating mild, 2 indicating moderate, and 3 indicating severe).

Secondary Outcome Measures

  1. Skin scaling, edema, and tearing [Standardized photos will be taken within 5 minutes of removing tape after surgery]

    Skin photographs will be independently evaluated by three blinded dermatologists to determine presence and severity of perioral scaling, edema, and tearing. Photographs will be cropped such that only the perioral region is visible for assessment. These outcomes will be evaluated on a scale of 0-3 (0 indicating none, 1 indicating mild, 2 indicating moderate, and 3 indicating severe).

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  1. Age ≥ 18

  2. Surgeries scheduled for anesthesia of duration more than 30 minutes after induction.

Exclusion Criteria:
  1. Any patient that does not consent

  2. Patients < 18 years old

  3. Surgery in the prone position

  4. Surgery on the head, brain, neck, teeth, mouth, eyes, or face

Any patient who has:
  1. Pre-existing skin erythema or other skin trauma

  2. Lips piercings

Contacts and Locations

Locations

Site City State Country Postal Code
1 Tufts Medical Center Boston Massachusetts United States 02141

Sponsors and Collaborators

  • Tufts Medical Center

Investigators

  • Principal Investigator: Andrea L Tsai, MD, Tufts Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Tufts Medical Center
ClinicalTrials.gov Identifier:
NCT03633877
Other Study ID Numbers:
  • IRB#: 13029
First Posted:
Aug 16, 2018
Last Update Posted:
Sep 14, 2021
Last Verified:
Sep 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 14, 2021